Emmaus Life Sciences, Inc. (EMMA) stock
EMMAOTCPharmaceutical PreparationsFiscal year ends December 31
$0.05−0.01 (-14.38%)
Close on Oct 19, 2026Market cap $6.03MP/E –Yield –
Emmaus Life Sciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Emmaus Life Sciences's revenue for the twelve months ending Jun 30, 2026 was $15.53M. For fiscal 2025 it was $12.45M, down 25.2% from the year before. Over ten years it grew 57.2% a year on average. The highest annual figure on record is $29.60M in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.45M | -25.2% |
| FY2024 | Dec 31, 2024 | $16.65M | -43.7% |
| FY2023 | Dec 31, 2023 | $29.60M | +60.9% |
| FY2022 | Dec 31, 2022 | $18.39M | -10.8% |
| FY2021 | Dec 31, 2021 | $20.61M | -11.0% |
| FY2020 | Dec 31, 2020 | $23.17M | +1.8% |
| FY2019 | Dec 31, 2019 | $22.75M | +17605.8% |
| FY2017 | Sep 30, 2017 | $128.50K | +51.0% |
| FY2016 | Sep 30, 2016 | $85.10K | -15.0% |
| FY2015 | Sep 30, 2015 | $100.10K | -25.9% |
| FY2014 | Sep 30, 2014 | $135.10K | +3.2% |
| FY2013 | Sep 30, 2013 | $130.90K | -82.5% |
| FY2011 | Sep 30, 2011 | $745.90K | +16.8% |
| FY2010 | Sep 30, 2010 | $638.50K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $6.32M | +91.9% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $1.98M | -63.8% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $3.85M | -28.4% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $3.38M | +34.8% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $3.29M | -53.4% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $5.48M | +9.2% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $5.38M | -50.0% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $2.51M | -62.9% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $7.07M | +19.2% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $5.02M | +1.6% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $10.76M | +151.0% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $6.75M | +108.8% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $5.93M | +96.4% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $4.94M | -14.3% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $4.29M | -33.9% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $3.23M | -39.4% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $3.02M | -51.7% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $5.77M | +2.9% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $6.49M | +48.8% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $5.34M | -23.3% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $6.25M | -50.2% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $5.60M | +2.0% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $4.36M | +12723.5% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $6.95M | +17112.9% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $12.55M | +39248.0% |
| Q3 FY2019CQ3 2018 | Jun 30, 2019 | $5.49M | +24643.2% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $34.00K | +82.8% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $40.40K | +91.5% |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $31.90K | +54.1% |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $22.20K | -10.1% |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $18.60K | -27.1% |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | $21.10K | -31.9% |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | $20.70K | -1.0% |
| Q1 FY2016CQ4 2015 | Dec 31, 2015 | $24.70K | +8.8% |
| Q4 FY2015CQ3 2015 | Sep 30, 2015 | $25.50K | – |
| Q3 FY2015CQ2 2015 | Jun 30, 2015 | $31.00K | – |
| Q2 FY2015CQ1 2015 | Mar 31, 2015 | $20.90K | – |
| Q1 FY2015CQ4 2014 | Dec 31, 2014 | $22.70K | – |
See a number that looks wrong?